AstraZeneca Announces Phase 3 LAURA Trial Results for Tagrisso Plus Bevacizumab in NSCLC

AstraZeneca today announced results from a Phase 3 trial evaluating Tagrisso (osimertinib) plus bevacizumab in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The trial demonstrated that the combination did not provide additional progression-free survival benefit compared to Tagrisso alone. These results suggest that adding bevacizumab to Tagrisso does not improve outcomes in unselected EGFR-mutated NSCLC patients. AstraZeneca will continue to analyze the data to identify potential biomarkers that may predict benefit from the combination. The company remains committed to advancing treatment options for EGFR-mutated NSCLC.